This is a U.S. news story, published by CNBC, that relates primarily to Recursion Pharmaceuticals news.
For more U.S. news, you can click here:
more U.S. newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
AI drug pioneer Recursion Pharmaceuticals. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest drug discovery platform news, experimental drug candidate news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
drug discovery company ExscientiaCNBC
•
75% Informative
AI drug pioneer Recursion Pharmaceuticals says one of its experimental treatments hit a key milestone.
The Food and Drug Administration cleared the drug application for a phase 1/2 clinical trial of an experimental drug candidate.
The potential market for this treatment could be more than 100,000 patients in the U.S. and EU .
VR Score
82
Informative language
86
Neutral language
61
Article tone
informal
Language
English
Language complexity
48
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links